Chen X, Zhang Q, Chen F, Wen S, Zhou C
Front Neurol. 2023; 14:1183823.
PMID: 37396766
PMC: 10312085.
DOI: 10.3389/fneur.2023.1183823.
Hacker M, Tramontana M, Pazira K, Meystedt J, Turchan M, Harper K
Parkinsonism Relat Disord. 2023; 113:105479.
PMID: 37380539
PMC: 11232874.
DOI: 10.1016/j.parkreldis.2023.105479.
Langlie J, Mittal R, Finberg A, Bencie N, Mittal J, Omidian H
Neural Regen Res. 2022; 17(10):2131-2140.
PMID: 35259819
PMC: 9083150.
DOI: 10.4103/1673-5374.335836.
Zhu J, Chen M
Medicine (Baltimore). 2021; 100(46):e27653.
PMID: 34797288
PMC: 8601351.
DOI: 10.1097/MD.0000000000027653.
Lin M, Mackie P, Shaerzadeh F, Gamble-George J, Miller D, Martyniuk C
Acta Neuropathol Commun. 2021; 9(1):107.
PMID: 34099060
PMC: 8185945.
DOI: 10.1186/s40478-021-01203-9.
Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.
Kiss B, Laszlovszky I, Kramos B, Visegrady A, Bobok A, Levay G
Biomolecules. 2021; 11(1).
PMID: 33466844
PMC: 7830622.
DOI: 10.3390/biom11010104.
Synergic control of action in levodopa-naïve Parkinson's disease patients: II. Multi-muscle synergies stabilizing vertical posture.
Freitas S, de Freitas P, Falaki A, Corson T, Lewis M, Huang X
Exp Brain Res. 2020; 238(12):2931-2945.
PMID: 33068173
PMC: 7644647.
DOI: 10.1007/s00221-020-05947-z.
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
Sy M, Fernandez H
Neurotherapeutics. 2020; 17(4):1331-1338.
PMID: 32935299
PMC: 7851218.
DOI: 10.1007/s13311-020-00924-4.
Sex-Dependent Improvement in Survival of Parkinson's Disease Patients.
Kuusimaki T, Kurki S, Sipila J, Salminen-Mankonen H, Carpen O, Kaasinen V
Mov Disord Clin Pract. 2020; 7(5):516-520.
PMID: 32626796
PMC: 7328416.
DOI: 10.1002/mdc3.12954.
Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements.
Lewis M, Harkins E, Lee E, Stetter C, Snyder B, Corson T
J Parkinsons Dis. 2020; 10(3):1075-1085.
PMID: 32538866
PMC: 8177750.
DOI: 10.3233/JPD-201932.
Synergic control of action in levodopa-naïve Parkinson's disease patients: I. Multi-finger interaction and coordination.
de Freitas P, Freitas S, Reschechtko S, Corson T, Lewis M, Huang X
Exp Brain Res. 2019; 238(1):229-245.
PMID: 31838566
DOI: 10.1007/s00221-019-05709-6.
Experimental manipulation of monoamine levels alters personality in crickets.
Abbey-Lee R, Uhrig E, Garnham L, Lundgren K, Child S, Lovlie H
Sci Rep. 2018; 8(1):16211.
PMID: 30385805
PMC: 6212410.
DOI: 10.1038/s41598-018-34519-z.
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Zhuo C, Zhu X, Jiang R, Ji F, Su Z, Xue R
Sci Rep. 2017; 8:45865.
PMID: 28374775
PMC: 5379205.
DOI: 10.1038/srep45865.
Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.
Dalvi A, Ford B
CNS Drugs. 2016; 9(4):291-310.
PMID: 27521014
DOI: 10.2165/00023210-199809040-00005.
Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials.
De Vecchis R, Cantatrione C, Mazzei D, Baldi C, Di Maio M
J Clin Med Res. 2016; 8(6):449-60.
PMID: 27222673
PMC: 4852778.
DOI: 10.14740/jocmr2541e.
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B
J Parkinsons Dis. 2016; 6(2):401-11.
PMID: 27061066
PMC: 4927859.
DOI: 10.3233/JPD-150758.
Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.
Thorlund K, Wu P, Druyts E, Eapen S, Mills E
Neuropsychiatr Dis Treat. 2014; 10:767-76.
PMID: 24855362
PMC: 4019622.
DOI: 10.2147/NDT.S60061.
Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.
van Boven J, Novak A, Driessen M, Boersma C, Boomsma M, Postma M
Drugs Aging. 2014; 31(3):193-201.
PMID: 24399580
DOI: 10.1007/s40266-013-0150-4.
The role of oxidative stress in Parkinson's disease.
Dias V, Junn E, Mouradian M
J Parkinsons Dis. 2013; 3(4):461-91.
PMID: 24252804
PMC: 4135313.
DOI: 10.3233/JPD-130230.
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.
Teo K, Ho S
Transl Neurodegener. 2013; 2(1):19.
PMID: 24011391
PMC: 3847108.
DOI: 10.1186/2047-9158-2-19.